Medical devices, healthcare technology and the business of care
PMA approval · P150013

PD-L1 IHC 22C3 PHARMDX

Agilent Technologies, Inc. · Decision date Oct 2, 2015

MEDTECHLEDGER EXPLANATIONP150013

What did the FDA approve?

The October 2, 2015 approval covers the PD-L1 IHC 22C3 pharmDx immunohistochemical assay from Agilent Technologies, Inc. The device detects PD-L1 protein in formalin-fixed, paraffin-embedded non-small cell lung cancer tissue using monoclonal mouse anti-PD-L1 clone 22C3, the EnVision FLEX visualization system, and Autostainer Link 48. Expression is scored by tumor proportion score, the percentage of viable tumor cells showing partial or complete membrane staining.

A specimen is considered PD-L1 positive when TPS is at least 50% of viable tumor cells with membrane staining at any intensity. The stated purpose is to aid in identifying NSCLC patients for treatment with Keytruda (pembrolizumab). The source statement reports that intended use; it does not itself establish safety or clinical effectiveness.

FDA approval order statement

APPROVAL FOR THE PD-L1 IHC 22C3 PHARMDX. THIS DEVICE IS INDICATED FOR THE FOLLOWING: PD-L1 IHC 22C3 PHARMDX IS A QUALITATIVE IMMUNOHISTOCHEMICAL ASSAY USING MONOCLONAL MOUSE ANTI-PD-L1, CLONE 22C3 ANTIBODY INTENDED FOR USE IN THE DETECTION OF PD-L1PROTEIN IN FORMALIN FIXED, PARAFFIN EMBEDDED (FFPE) NON-SMALL CELL LUNG CANCER (NSCLC) TISSUE USING ENVISION FLEX VISUALIZATION SYSTEM ON AUTOSTAINER LINK 48. PD-L1 PROTEIN EXPRESSION IS DETERMINED BY USING TUMOR PROPORTION SCORE (TPS), WHICH IS THE PERCENTAGE OF VIABLE TUMOR CELLS SHOWING PARTIAL OR COMPLETE MEMBRANE STAINING. THE SPECIMEN SHOULD BE CONSIDERED PD-L1 POSITIVE IF TPS >= 50% OF THE VIABLE TUMOR CELLS EXHIBIT MEMBRANE STAINING AT ANY INTENSITY. PD-L1 IHC 22C3 PHARMDX IS INDICATED AS AN AID IN IDENTIFYING NSCLC PATIENTS FOR TREATMENT WITH KEYTRUDA (PEMBROLIZUMAB).
Regulatory pathway
Original PMA
Clinical specialty
Pathology
Decision date
Oct 2, 2015

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P150013
Regulatory pathway
Premarket approval application
Product code
PLS
Decision code
APPR
Decision date
Oct 2, 2015
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Immunohistochemistry assay, antibody, programmed death-ligand 1.

Product code
PLS
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P150013 received

    Application receipt date recorded by FDA.

  2. P150013 · FDA decision

    APPR

Timeline entries are records held by MedtechLedger for P150013. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P150013

Product / regulatory recordCompanyPathwayDecision dateSource
Agilent Technologies, Inc.PMA supplementSep 11, 2026FDA
Agilent Technologies, Inc.PMA supplementSep 21, 2026FDA

Explore the linked device profile

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Agilent Technologies, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
5301 Stevens Creek Blvd., Santa Clara, CA, 95051

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records